SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): May 10, 2004
OSCIENT PHARMACEUTICALS CORPORATION
(Exact name of registrant as specified in its charter)
| Massachusetts | 0-10824 | 04-2297484 | ||
| (State or other jurisdiction of incorporation) |
(Commission File Number) | (I.R.S. Employer Identification Number) |
100 Beaver Street
Waltham, Massachusetts 02453
(Address of principal executive offices, including zip code)
(781) 398-2300
(Registrant’s telephone number, including area code)
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
| 99.1 | Press Release issued by Oscient Pharmaceuticals Corporation on May 10, 2004. |
ITEM 12. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.
On May 10, 2004, Oscient Pharmaceuticals Corporation issued a press release announcing its financial results for its first fiscal quarter ended December 31, 2003. A copy of that press release is furnished with this Current Report on Form 8-K as Exhibit 99.1.
The information in this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, regardless of any general incorporation language in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| GENOME THERAPEUTICS CORP. | ||
| By: |
/s/ Stephen Cohen | |
| Name: |
Stephen Cohen | |
| Title: |
Senior Vice President and | |
Date: May 14, 2004
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press Release issued by Oscient Pharmaceuticals Corporation on May 10, 2004. |